Cumberland Pharmaceuticals Inc. (CPIX)

NASDAQ: CPIX · IEX Real-Time Price · USD
2.140
-0.070 (-3.17%)
Feb 23, 2024, 4:30 PM EST - Market closed
-3.17%
Market Cap 31.90M
Revenue (ttm) 39.32M
Net Income (ttm) -2.43M
Shares Out 14.90M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,373
Open 2.089
Previous Close 2.210
Day's Range 1.900 - 2.214
52-Week Range 1.430 - 2.560
Beta 0.18
Analysts n/a
Price Target n/a
Earnings Date Mar 5, 2024

About CPIX

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infect... [Read more]

Sector Healthcare
IPO Date Aug 11, 2009
Employees 85
Stock Exchange NASDAQ
Ticker Symbol CPIX
Full Company Profile

Financial Performance

In 2022, CPIX's revenue was $42.01 million, an increase of 16.75% compared to the previous year's $35.99 million. Losses were -$5.57 million, 58.8% more than in 2021.

Financial Statements

News

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands de...

3 months ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financi...

4 months ago - PRNewsWire

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

NASHVILLE, Tenn. , Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy 1 detailing the results of th...

4 months ago - PRNewsWire

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

NASHVILLE, Tenn. , Aug. 8, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favor...

7 months ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

NASHVILLE, Tenn. , Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financ...

7 months ago - PRNewsWire

NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS

NASHVILLE, Tenn. , June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical...

8 months ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial, Newest program in Cumberland's ifetroban pipeline NASHVILLE, Tenn. , May 23, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nas...

9 months ago - PRNewsWire

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

Caldolor® is the only injectable non-opioid approved for treating pain in infants NASHVILLE, Tenn. , May 15, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceut...

10 months ago - PRNewsWire

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update

NASHVILLE, Tenn. , May 9, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that the Company's product portfolio of FDA-approved ...

10 months ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

NASHVILLE, Tenn. , May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financia...

10 months ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022

2022 highlights include its acquisition of Sancuso ® and move to new headquarters NASHVILLE, Tenn. , March 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceu...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

NASHVILLE, Tenn. , Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial res...

1 year ago - PRNewsWire

Cumberland Pharmaceuticals Reports 41% Revenue Growth

Company Also Delivers Growing Cash Flow from Operations NASHVILLE, Tenn. , Nov. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced to...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS

NASHVILLE, Tenn. , Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financia...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST

NASHVILLE, Tenn. , Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today th...

1 year ago - PRNewsWire

Cumberland Pharmaceuticals Reports 14% Revenue Growth

Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn. , Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical compan...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021

The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues NASHVILLE, Tenn. , Aug. 8, 2022 /PRNewswire/ -- Cumberland Ph...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

NASHVILLE, Tenn. , Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financi...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

NASHVILLE, Tenn. , July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Boar...

1 year ago - PRNewsWire

Cumberland Pharmaceuticals Reports 6% Revenue Growth

The Nashville-based specialty pharmaceutical company issues  first quarter 2022 financial results and a company update NASHVILLE, Tenn. , May 10, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (...

1 year ago - PRNewsWire

Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®

Verity Pharmaceuticals will feature Sancuso across the U.S.  through its established oncology commercial organization and customer network NASHVILLE, Tenn. , May 9, 2022 /PRNewswire/ -- Specialty phar...

1 year ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS

NASHVILLE, Tenn. , May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financia...

1 year ago - PRNewsWire

TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST

Vibativ ®  treats patients with multidrug-resistant infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, March 31, 2022 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals I...

2 years ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE

NASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a compa...

2 years ago - PRNewsWire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS

NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results ...

2 years ago - PRNewsWire